August 2026 brought no new federal treatment-policy change for hormones and acne: the FDA postponed planned iPLEDGE changes from August 8 to November 15, 2026. For now, follow existing isotretinoin testing instructions, weigh topical clascoterone realistically, and treat topical spironolactone as investigational. An antiandrogen targets the androgen receptor; clascoterone does this through a cream applied to the skin. It differs from systemic options such as combined oral contraceptives and oral spironolactone.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Did the August iPLEDGE change take effect?
- What changed for topical antiandrogen treatment?
- How do the available options differ?
- What should readers watch next?
Did the August iPLEDGE change take effect?
No. On June 16, the FDA postponed the iPLEDGE REMS modifications until November 15, 2026. The agency also continued its existing enforcement discretion for pregnancy-testing requirements. iPLEDGE is the pregnancy-risk safety system for isotretinoin.
Once the modifications take effect, prescribers may allow at-home pregnancy tests during and after treatment. Pretreatment tests must still occur in a medical setting, according to the FDA's February 2026 notice. The delay changes timing, not the instructions patients should follow today. Anyone taking or preparing to take isotretinoin should confirm accepted test locations and deadlines with the prescribing clinic rather than assuming a home result will qualify.
What changed for topical antiandrogen treatment?
Europe's notable recent change happened before August. The European Medicines Agency says Winlevi received EU-wide authorization on October 17, 2025, for adults with acne and for facial acne in adolescents ages 12 through 17. In the United States, clascoterone is approved for patients ages 12 and older. It offers people of any sex an androgen-targeted topical option without requiring an oral hormone drug. The evidence supports modest expectations.
In two 12-week trials, label-defined treatment success reached 18.8% and 20.9% with clascoterone, compared with 8.7% and 6.6% using the vehicle. That equals improvements of 10.1 and 14.3 percentage points, but 91% of the 1,421 participants were White, limiting how confidently the results generalize across populations. Topical treatment does not mean zero systemic effect. The U.S. DailyMed label reports suppression of the body's adrenal-hormone control system in one of 20 adults and two of 22 adolescents after two weeks. All recovered by the four-week follow-up, and the label also warns about local irritation.
How do the available options differ?
Current American Academy of Dermatology guidance supports three androgen-related approaches: topical clascoterone, combined oral contraceptives, and oral spironolactone. They are alternatives to discuss, not interchangeable versions of the same treatment. Clascoterone acts locally and is approved from age 12.
Combined oral contraceptives and spironolactone are systemic options, meaning the medicine works throughout the body. The supplied evidence does not establish that one choice is best for every acne pattern or patient. Useful questions for a treatment discussion include: The AAD also urges clinicians to limit systemic-antibiotic use and combine topical therapies where appropriate. That makes the broader treatment plan important: an androgen-targeted medicine may be one component rather than the entire regimen.
- Is the treatment approved for your age and location?
- Do you prefer a topical treatment or want to consider a systemic option?
- How will progress and side effects be assessed?
- Could local irritation affect consistent use?
- If isotretinoin is being considered, which pregnancy tests will the clinic accept?
What should readers watch next?
The next scheduled iPLEDGE milestone is November 15, 2026. Watch for updated FDA and clinic instructions before changing how pregnancy testing is completed; the postponement itself does not confirm that implementation will proceed without another revision. Topical spironolactone remains a research question.
ClinicalTrials.gov lists a 40-participant Phase 2 split-face study comparing 5% topical spironolactone with adapalene. In a split-face study, different treatments are tested on opposite sides of each participant's face. The record lists primary completion in October 2026 and final completion in December 2026. Until results are available, this study is not evidence that topical spironolactone is an established acne treatment.